US Stock Market Move | Trex Bio (TRXB.US) debuts on the U.S. stock market, falling more than 1.3% after the open.
As of press time, the stock fell more than 1.3% to $13.805.
On Friday, Trex Bio (TRXB.US) debuted on the U.S. stock market. As of press time, the stock fell more than 1.3% to $13.805. The IPO price was $14. TRex Bio is a clinical-stage biopharmaceutical company dedicated to developing drugs that enhance the function of regulatory T cells (Tregs) in inflamed human tissues, with the goal of restoring immune balance and repairing barrier damage rather than broadly suppressing the immune system. Its Deep Biology platform is capable of mapping Treg function in human skin, gut, and lung tissues to identify targets, which are then validated through proprietary in vitro Treg models and high-throughput functional assays.
Related Articles
US Stock Market Move | U.S. clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuted on the U.S. stock market, with its share price falling more than 10% after the opening bell.
US Stock Market Move | Included in the Nasdaq 100 Index, Moderna (MRNA.US) rises 7%.
US Stock Market Move | Snap (SNAP.US) rises over 6% as hedge fund urges bringing in outside capital for Specs, which could unlock shareholder value.
US Stock Market Move | U.S. clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuted on the U.S. stock market, with its share price falling more than 10% after the opening bell.
US Stock Market Move | Included in the Nasdaq 100 Index, Moderna (MRNA.US) rises 7%.
US Stock Market Move | Snap (SNAP.US) rises over 6% as hedge fund urges bringing in outside capital for Specs, which could unlock shareholder value.
